A Phase I Trial of Pox PSA vaccines (PROSTVAC(®)-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM™) in Patients with Prostate Cancer

PURPOSE: Based on previous studies that demonstrated the safety profile and preliminary clinical activity of prostate specific antigen (PSA) targeted therapeutic vaccines, as well as recent laboratory data supporting the value of the addition of co-stimulatory molecules B7-1, ICAM-1, and LFA-3 (desi...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: DiPaola, RS, Plante, M, Kaufman, H, Petrylak, DP, Israeli, R, Lattime, E, Manson, K, Schuetz, T
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2006
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC1360095/
https://ncbi.nlm.nih.gov/pubmed/16390546
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1479-5876-4-1
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars